Detalles de la búsqueda
1.
Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial.
JAMA
; 320(2): 146-155, 2018 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29998336
2.
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
Am Heart J
; 177: 74-86, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27297852
3.
Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial.
Am Heart J
; 175: 77-85, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27179726
4.
The treatment of missing data in a large cardiovascular clinical outcomes study.
Clin Trials
; 13(3): 344-51, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26908543
5.
Novel oral anticoagulants and reversal agents: Considerations for clinical development.
Am Heart J
; 169(6): 751-7, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26027611
6.
Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans.
Int J Clin Pharmacol Ther
; 50(8): 584-94, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22578199
7.
Three year clinical outcomes in a nationwide, observational, siteless clinical trial of atrial fibrillation screening-mHealth Screening to Prevent Strokes (mSToPS).
PLoS One
; 16(10): e0258276, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34610049
8.
Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults.
PLoS One
; 16(5): e0251963, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34029345
9.
Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
J Cardiovasc Pharmacol
; 55(5): 459-68, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20051879
10.
Healthcare resource utilization following ECG sensor patch screening for atrial fibrillation.
Heart Rhythm O2
; 1(5): 351-358, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34113893
11.
Digital recruitment and enrollment in a remote nationwide trial of screening for undiagnosed atrial fibrillation: Lessons from the randomized, controlled mSToPS trial.
Contemp Clin Trials Commun
; 14: 100318, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30656241
12.
Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
Thromb Res
; 119(1): 121-7, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-16448687
13.
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Thromb Haemost
; 95(3): 447-53, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16525572
14.
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
J Am Coll Cardiol
; 41(4): 557-64, 2003 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-12598065
15.
Incidence of ischemic stroke or transient ischemic attack in patients with multiple risk factors with or without atrial fibrillation: a retrospective cohort study.
Curr Med Res Opin
; 31(7): 1257-66, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25877807
16.
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.
Clin Cardiol
; 38(2): 63-8, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25588595
17.
Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
Thromb Haemost
; 87(2): 300-5, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11858491
18.
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Thromb Haemost
; 91(6): 1090-6, 2004 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15175794
19.
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Clin Pharmacokinet
; 42(5): 485-92, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12739986
20.
No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
J Clin Pharmacol
; 44(8): 935-41, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15286098